Illumina, Inc. announced today that Mark Van Oene has been named Chief Commercial Officer. Van Oene was previously Illumina’s Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016.
“Mark is a great leader for our commercial organization, possessing deep genomics expertise and over a decade of experience building and running strong sales and marketing teams,” said Francis deSouza, Illumina President and Chief Executive Officer. “As interim Chief Commercial Officer Mark has guided Illumina through two strong quarters, including the launch of NovaSeq, and laid the foundation for our future growth. I am excited to continue to work closely with Mark to expand our commercial capability as we grow in research and clinical markets around the world.”
Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. In 2008, Van Oene was promoted to Senior Director of Sales for the Americas. Four years later, he was promoted to Vice President with responsibility for global sales. From 2012 through 2014, Van Oene led the team to grow revenues from $1.06B to $1.42B. In early 2014, Van Oene was named the General Manager for the Americas region, advancing to Senior Vice President in April 2016. During that time, the Americas compound annual growth rate exceeded 20%.
As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at Illumina. He will report to President and CEO, Francis deSouza.
Van Oene earned a Bachelor of Science degree in Biochemistry from Western University in London, Ontario, Canada.
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.